Sosei : Notice of Issuance of New Shares Under Restricted Stock Unit (RSU) Plan

PRESS RELEASE

Notice of Issuance of New Shares Under Restricted Stock Unit (RSU) Plan

Tokyo, Japan and London, UK, 1 April 2021 - Sosei Group Corporation ("the Company"; TSE: 4565) announces that the Company has determined the details of issuance of new shares under the Restricted Stock Unit ("RSU") Plan No. 4 as set forth below ("the Share Issuance") as announced by the Company in Press Release "Notice of Issuance of New Shares Under Restricted Stock Unit (RSU) Plan" issued on 11 December 2019.

(1)	Payment date		16 April 2021
(2)	Type	and	number	151,918 shares of the Company's common stock
	of shares	to	be
	issued
(3)	Payment amount	1,972 Yen per share
(4)	Total	amount	of	299,582,296 Yen
	payment
(5)	Allottees			7 Director and Executive Officers of the Company
					55 Directors of subsidiaries of the Company and employees of the
					Company and its subsidiaries
(6)	Other details		The Securities Registration Statement relating to the Share Issuance
					has been filed in accordance with the Financial Instruments and
					Exchange Act.
(Note)

1. The aforementioned payment amount per share has been determined by the Representative Executive Officer as at the closing price of the Company's shares on the Tokyo Stock Exchange on the day immediately prior to the Date of Determination (20 April 2021). The payment amount per share is the market share price immediately preceding the Date of the Determination, so the Company considers it is not issuance of shares at a particularly favorable value.
2. The Company will deliver the aforementioned new shares to be issued to the Allottees in exchange for provision as contribution in kind of monetary compensation claims against the Company provided to the Allottees.
3. The Performance Period for the Share Issuance was from 1 April 2019 to 31 March 2021.

-ENDS-

PRESS RELEASE

About Sosei Heptares

We are an international biopharmaceutical group focused on the discovery and early development of new medicines originating from our proprietary GPCR-targeted StaR® technology and structure-based drug design platform capabilities. We are advancing a broad and deep pipeline of novel medicines across multiple therapeutic areas, including neurology, immunology, gastroenterology and inflammatory diseases.

We have established partnerships with some of the world's leading pharmaceutical companies, including AbbVie, AstraZeneca, Biohaven, Genentech (Roche), GSK, Novartis, Pfizer and Takeda and additionally with multiple emerging technology companies. Sosei Heptares is headquartered in Tokyo, Japan with corporate and R&D facilities in Cambridge, UK.

"Sosei Heptares" is the corporate brand and trademark of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565). Sosei, Heptares, the logo and StaR® are trademarks of Sosei Group companies.

For more information, please visit https://www.soseiheptares.com/

LinkedIn:@soseiheptaresco| Twitter:@soseiheptaresco| YouTube:@soseiheptaresco

Enquiries:

Sosei Heptares - Media and Investor Relations

Hironoshin Nomura, SVP Investor Relations and Corporate Strategy [phone] | [e-mail]

Shinichiro Nishishita, VP Investor Relations, Head of Regulatory Disclosures [phone] | [e-mail]

Citigate Dewe Rogerson (for Sosei Heptares)

Yas Fukuda - Japanese Media

[phone] |[e-mail]

Mark Swallow, David Dible - International Media

[phone] |[e-mail]

Forward-looking statements

This press release contains forward-looking statements, including statements about the discovery, development and commercialization of products. Various risks may cause Sosei Group Corporation's actual results to differ materially from those expressed or implied by the forward- looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.